| ID | 1176 |
| Name of the vaccine | CTH522 |
| Microbe | Bacteria |
| Disease name | Chlamydia |
| Name of bacteria | Chlamydia trachomatis |
| Type of vaccine | Recombinant |
| Nucleic acid content | DNA |
| Age | Women of 18 to 45 years |
| Description of the vaccine | Recombinant protein subunit adjuvanted vaccine. |
| Name of the manufacturer | Statens Serum Institut |
| Name of the manufacturing country | United Kingdom |
| Year of manufacture | 2017 |
| Clinical Phase status | Clinical - Phase 1 |
| Bacterial strain | Gram-negative bacteria, coccoid or rod shape. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Four vaccinations. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | Prevents chlamydia. |
| Export | NA |
| Approval | NA |
| Adjuvant | CAF01, aluminium hydroxide |
| Repurposing | NA |
| Side effects of vaccine | Mild local injection-site reactions. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | 31416692 |
| Clinical trial number | NCT02787109 |
| Reference | https://www.precisionvaccinations.com/vaccines/cth522-chlamydia-vaccine |
| Other name | NA |
| Additional Links | NA
|